|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Emerging Therapies and Therapeutic Targets in Prostate Cancer
|
Mark Rubin, MD
Mark Rubin joins Alicia Morgans to discuss emerging therapies and emerging therapeutic targets in prostate cancer. Topics covered include types of resistance, epigenetic therapies, and EZH2 inhibitors. Dr. Rubin also shares his thoughts on how he sees molecular pathology impacting cancer care in the next decade.
|
|
|
|
|
|
|
|
|
|
|
|
Associations of Circulating Cell-Free DNA (cfDNA) and Clinical Outcomes in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): A Discussion on the Data
|
|
Daniel H. Shevrin, MD
|
| Joining Alicia Morgans is Daniel Shevrin to discuss questions that still remain regarding the validity of cell-free DNA assays, particularly for non-DDR genes, and how this analysis is helping to get a better understanding of the associations of these gene alterations with the cell-free DNA assay in relevant clinical outcomes.
|
|
|
|
|
|
|
|
|
|
|
|
| Tazemetostat in Combination With Abiraterone + Prednisone or Enzalutamide in mCRPC |
| Wassim Abida, MD |
| In this UroToday discussion, Wassim Abida joins Alicia Morgans to provide a background of the study and to share the results of an analysis of the safety and efficacy of tazemetostat in combination with abiraterone/prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
| Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms - Beyond the Abstract |
| Geoffrey Oxnard, MD |
| Foundation Medicine and its collaborators recently announced results from a prostate cancer study evaluating the landscape of genomic alterations identified by liquid biopsy in over 3,000 patients and assessing concordance of liquid and tissue biopsy in over 800 patients. The study demonstrated high concordance between targetable alterations identified using circulating tumor DNA (ctDNA) and tissue-based comprehensive genomic profiling (CGP) in patients with metastatic castration-resistant prostate cancer (mCRPC). |
|
|
|
|
|
| Molecular Pathology to Advance Prostate Cancer Precision Medicine
|
| Mark Rubin, MD
|
| In this presentation, Mark Rubin discusses the role of molecular pathology to guide treatment for patients with advanced prostate cancer. He begins by emphasizing insights into how molecular alternations that occur in the tumorigenesis pathway may influence therapy. It is particularly important to consider those that may confer treatment resistance.
|
|
|
|
|
|
|
|
|
| Molecular Pathology Before Systemic Treatment - What is Feasible?
|
| Sven Perner, MD, Ph.D.
|
| In this discussion, Sven Perner elaborates on the various molecular subtypes of prostate cancer. Dr. Perner also mentions that amplification, mutation, and splicing variants of androgen receptor variants (AR-V7) are frequent and relevant in castration-resistant prostate cancer.
|
|
|
|
|
|
| Discussant: Promising Therapeutic Targets in Prostate Cancer
|
| Ana Aparicio, MD
|
| Ana Aparicio provides her perspective on promising emerging therapeutic targets in prostate cancer. She discusses three posters assessing novel treatment approaches in advanced prostate cancer, “TRANSFORMER: Bipolar androgen therapy vs enzalutamide for mCRPC”, “A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies”, and “ProCAID: A randomized double-blind phase II clinical trial of capivasertib in combination with docetaxel and prednisolone chemotherapy in mCRPC".
|
|
|
|
|
|
| Mechanisms of Resistance to Radiopharmaceuticals |
| Johannes Czernin, MD |
| The 2022 GU ASCO Annual meeting included a session on novel treatment implementation focusing on PSMA targeting and beyond, with a presentation by Dr. Johannes Czernin discussing mechanisms of resistance to radiopharmaceuticals. Dr. Czernin started by emphasizing that we can have remarkable treatment responses to 177Lu-PSMA-617. |
|
|
|
|
|
| Discussant: Novel Biomarkers in Prostate Cancer: Is the Tissue the Issue? |
| David R. Wise, MD, Ph.D. |
| David Wise provides a discussant presentation for important abstracts assessing the impact of circulating tumor cells as prognostic factors in the management of advanced prostate cancer. There are many treatment intensification strategies for advanced prostate cancer, the majority of which are guided by disease risk biology, as well as age and performance status. |
|
|
|
|
|
|
